CarotidWALLSTENTTM

頸動脈支架?支架自膨支架Elgiloy?

金屬絲編制管狀網眼結構2支架輸送系統Monorail?導管設計，0.014“導絲輸送系統；5F(6&8mm)和6F(10mm)低外廓，高柔順性；

CarotidWALLSTENTTM

頸動脈支架閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM

頸動脈支架閉環單元結構，獨特的支架設計提供最大化的斑塊覆蓋高度的柔順性便于使用的輸送系統*FreeCellArea:Measurestheaveragearea(mm2)withintheperimeterofconnectingstruts.Smallernumber=smallerfreecellarea.CarotidWALLSTENTTM

頸動脈支架支架設計-閉環

Vs.開環閉環支架設計CarotidWALLSTENT?EndoprosthesisXact?CarotidStent開環支架設計Precise?PRORx

NitinolStentSystemRXAcculink?CarotidStentCarotidWALLSTENTEndoprosthesisPrecisePRORxNitinolStentSystemRXAcculinkCarotidStentImagestakenbyandonfileatBSC.IllustrationsbyBSC.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.閉環支架設計CWS與其他頸動脈支架相比，具有最小的支架網孔面積**CarotidWALLSTENT?

閉環設計提供最大化的斑塊覆蓋以及光滑平整的管腔

**TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof<8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.*FreeCellArea:測量支架連接小桿周長間的平均面積數值越小=支架網孔面積越小PhotographstakenbyBostonScientificCorporation閉環支架設計CarotidWALLSTENT?

閉環設計提供最大化的斑塊覆蓋以及光滑平整的管腔

DoesCarotidStentDesignInfluenceOutcomes?

R.M.Bersin,CatheterizationandCardiovascularInterventions2008;72:863–866目前為止，已經完成3項有關頸動脈支架設計與臨床結果的回顧性、非隨機研究。DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.Aretrospectiveanalysisof30dayoutcomesofacarotidarterystentingmulticenterdatabaseconsistingof3179consecutivepatientsSPACE,aretrospective,randomizedtrialofcarotidarterystentingversusendarterectomyinstandardsurgicalriskpatientswithsymptomaticcarotidarterystenosesSchillingerM,GschwendtnerM,ReimersB,etal.Doescarotidstentcelldesignmatter?Aretrospective,nonrandomizedreviewofacarotidarterystentingmulticenterdatabaseconsistingof1,684consecutivepatientsDoesCarotidStentDesignInfluenceOutcomes?

Bersin.CatheterizationandCardiovascularInterventions2008;72:863–866..DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.目的:明確頸動脈支架設計，尤其是支架網孔面積，對于頸動脈支架術后30天卒中、死亡或TIA的影響。

30天結果的回顧性分析TIA，死亡,大和小卒中(非心肌梗死)共3179接受頸動脈支架手術的患者4個中心Bosiers,Deloose-BelgiumPeeters,Verbis-BelgiumSetacci,Donatoetal.-ItalyCremonesi,Castriota-ItalyDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.DoesFreeCellAreaInfluencetheOutcomein

CarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.

閉環支架定義為支架網孔面積<5.0mm2例如CarotidWALLSTENT?EndoprosthesisXACT?Carotid

Stent開環支架定義為支架網孔面積>5.0mm2例如Precise?Rx

NitinolStentSystemRXAcculink?CarotidStentDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.PreciseisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.第30天事件：閉環

vs.開環支架設計

TIA,死亡,大和小卒中DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.對于癥狀性患者，術后第30天的主要事件發生率差異顯著開環支架設計(7.0%)VS

閉環支架設計(2.2%)(p<0.0001)DoesFreeCellAreaInfluencetheOutcomein

CarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.

N=3179P=0.005N=1317P<0.0001N=1862P=1.0DoesFreeCellAreaInfluencetheOutcomein

CarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.

術后=(TIA,卒中,死亡)直到術后30天發生閉環

vs.開環支架設計DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.對于癥狀性患者，手術30天以后的主要事件發生率差異顯著開環支架設計(6.3%)VS閉環支架設計(1.3%)(p<0.0001)N=3179P<0.0001N=1317P<0.0001N=1862P=1.0患者評估由獨立神經病學醫師進行神經學上的局限性回顧性的研究非隨機設計可能導致在選擇時會因特定病變類型有所偏向注冊數據受制于自我審計技術復雜性沒有評估，結果沒有經過風險校正有必要進行前瞻性的隨機研究來比較不同支架網孔面積以得到最終結論DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.DoesFreeCellAreaInfluencetheOutcomein

CarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.

總結四個中心的30天結果回顧性分析N=3179CASpatients對于癥狀性患者，術后第30天的主要事件發生率差異顯著，開環支架設計(7.0%)VS閉環支架設計(2.2%)(p<0.0001)對于癥狀性患者，手術30天以后的主要事件發生率差異顯著，開環支架設計(6.3%)VS閉環支架設計(1.3%)(p<0.0001)DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.DoesFreeCellAreaInfluencetheOutcomein

CarotidArteryStenting?

Bosiersetal.EurJVascEndovascSurg2007;33:135-141.

CarotidWALLSTENT?Endoprosthesis閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydisease跟蹤性極佳的SDS-支架輸送系統獨特的編織結構提高支架的柔順性CarotidWALLSTENT?具有高度柔順的輸送系統，提供卓越的跟蹤性以通過扭曲病變TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof<8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.DeliveryForce:Benchtestthatmeasuresthemaximumforcerequiredtonavigatethroughabenchmodeloftortuosity.Smallervalues=Lessforcerequired低外廓的輸送系統直徑≤8mm直徑>8mmCarotidWALLSTENT?Endoprosthesis5F6FXact?CarotidStent6F6FRXAcculink?CarotidStent6F6FPrecise?PRORxNitinolStentSystem5F6F匹配的導引鞘*(VesselSize)*InformationexcerptedfromrespectiveDFUs.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.低外廓設計允許其通過5For6F血管鞘

CarotidWALLSTENT?的低外廓支架輸送系統使其具有卓越的跟蹤性以通過迂曲的解剖結構便于使用Thepin-and-pulldeliverysystemisdesignedtosimplifydeliveryCarotidWALLSTENT?EndoprosthesisDeliverySystemFinalAssembly.ImagepropertyofBostonScientificCorporation.Notnecessarilytoscale.閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM

頸動脈支架出色的顯影性在對比測試中，與其他頸動脈支架相比，CarotidWALLSTENT是顯影性最好的支架CarotidWALLSTENT?的設計使支架具有高度可視性，便于支架的精確釋放TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof<8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.Xact?StentProtege?StentRXAcculink?StentPrecise?

ProNitinolStentCarotidWALLSTENTRadiopacity:BenchtestthatillustratesthevisibilityofastentunderC-armunderneathsimulatedtissueImagecourtesyofDr.Hoffman

IllustratestheinvivovisibilityofCarotidWALLSTENTandtheRxAcculinkCarotidstent.Maynotbeindicativeofclinicalperformance..

AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,CarotidWALLSTENT?EndoprosthesisRXAcculink?CarotidStent出色的顯影性出色的顯影性DistalInnerROMarkerOuterDistalROMarkerAllPhotographstakenbyBostonScientificCorporation內桿及外鞘上的可回收標記點均不透射線，幫助支架的定位閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM

頸動脈支架獨特的可回收能力**Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.CarotidWALLSTENT?的獨特設計使其可以重新回收再釋放，幫助支架的精確釋放獨特的導管結構和支架設計使支架在其在釋放少于50%時都可以回收再釋放DFU中與回收相關的注意事項*:只有在必要時才進行回收當支架已解除斑塊時，應該嚴格避免回收回收次數不能超過2次不可回收標記點CarotidWALLSTENT?EndoprosthesisDeliverySystemFinalAssembly.ImagepropertyofBostonScientificCorporation.Notnecessarilytoscale.*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.獨特的可回收能力*顯示支架回縮的“不可回收點”只要外鞘的回撤未超過不可回收標記點，醫生都可以對支架進行回收重新釋放（不超過2次，未接觸斑塊）閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM

頸動脈支架閉環設計跟蹤性極佳的SDS-支架輸送系統卓越的顯影性獨特的可回收能力*

唯一經FDA批準可用于雙側治療頸動脈支架**臨床數據支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM

頸動脈支架28尺寸的正確選擇CarotidWALLSTENTTM

頸動脈支架CarotidWALLSTENT?Monorail?支架輸